Articles from Frazier Healthcare Partners

Frazier Healthcare Partners, a private capital firm focused exclusively on the healthcare industry, is pleased to announce the launch of Frazier Healthcare Structured Solutions, a new investment vertical at the firm focused on providing flexible capital to lower middle market healthcare companies. This initiative is designed to complement the private equity flagship strategy and provide attractive risk-adjusted returns for investors.

Frazier Healthcare Partners (“Frazier”), a Seattle-based, healthcare-focused investment firm, announced today that it has completed the acquisition of DirectMed Imaging (“DirectMed” or the “Company”), a leading provider of aftermarket parts and component repairs for diagnostic imaging equipment, from NMS Capital.

Frazier Healthcare Partners, a private equity firm focused exclusively on the healthcare industry, is pleased to announce that Willis Chandler has joined the firm’s Growth Buyout team as an Executive in Residence. Mr. Chandler will work alongside the firm to develop and execute investment strategies focused on pharma and pharmacy services. In this role, he will focus on the sourcing, diligence, and leadership of a new platform investment for Frazier.

Frazier Healthcare Partners today announced the promotion of Clarissa Berman to Principal on the Growth Buyout Investment Professional (IP) team.

Frazier Healthcare Partners (“Frazier”), a Seattle-based, healthcare-focused investment firm, announced today that it has completed its acquisition of BioMatrix Holdings, LLC (“BioMatrix” or the “Company”).

Frazier Healthcare Partners, a leading private equity firm focused exclusively on the healthcare industry, is pleased to announce the additions of three experienced professionals to its Center of Excellence: Sanji Fernando, Partner – Data & Artificial Intelligence, Steve Blackhart, Vice President – Corporate Development, and Lindsey Murphy, Director – Sales Operations.

Frazier Healthcare Partners, a leading private equity and venture capital firm focused exclusively on the healthcare industry, is pleased to announce that Maria Molland has joined the firm’s Growth Buyout team as an Executive in Residence. Ms. Molland will work alongside the firm to develop and execute investment strategies focused on women’s health and wellness, with a particular emphasis on tech-enabled products and services supporting women through their reproductive and post-partum journeys. In this role, Ms. Molland will focus on the sourcing, diligence, and leadership of a new platform investment for Frazier.

Frazier Healthcare Partners (Frazier), a Seattle-based, healthcare-focused investment firm, announced today that it has completed its acquisition of RevSpring (“RevSpring” or the “Company”), a leading provider of end-to-end communication and payment solutions servicing healthcare and financial services companies, from leading private equity firm GTCR. Frazier is joined in the transaction by NEA, 22C Capital, and RevSpring’s senior leadership team.

Frazier Healthcare Partners, a leading healthcare investment firm, today announced Peter Tornatore has joined the Frazier Healthcare Growth Buyout Investor Relations team as a Vice President.

Frazier Healthcare Partners, a leading healthcare investment firm, today announced the promotion of Shyamal Swami to Principal on the Growth Buyout team.

Frazier Healthcare Partners, a leading healthcare investment firm, today announced the promotions of Kent Berkley and Ryan Lucero to Partner on the Growth Buyout Investment team.

Frazier Healthcare Partners, a leading private equity and venture capital firm focused exclusively on the healthcare industry, is pleased to announce the promotion of Andy Caine to the new role of Chief Operating Officer/Partner for the Center of Excellence Team. Andy joined Frazier’s Growth Buyout Team in the spring of 2018 as the Partner leading our Human Capital efforts. More recently, he added to his responsibilities all aspects of the firm’s industry-leading ESG and DEIA efforts. During his tenure with the firm, he oversaw the scaling of the Human Capital team and was directly involved with the growth of the Center of Excellence group from three to seventeen team members today. He brings expertise in organization and human capital management, focusing on pre-investment organizational due diligence, talent assessment and development, and post-acquisition management for Frazier's Growth Buyout portfolio companies.

Frazier Healthcare Partners, a leading private equity and venture capital firm focused exclusively on the healthcare industry, is pleased to announce that Amy DuRoss has joined the firm’s Growth Buyout team as a Senior Advisor. In this role, Ms. DuRoss will help the firm build and execute investment strategies to serve the growing pharmaceutical and life sciences markets. This work will be complementary to Ms. DuRoss’ new role as President, Cell and Gene Therapies (CGT) for CSafe Global (“CSafe”), a Frazier portfolio company.

Frazier Healthcare Partners, a leading healthcare investment firm, today announced several promotions on the Growth Buyout team and the addition of Dr. Deneen Vojta as Senior Advisor.

Frazier Healthcare Partners, a leading healthcare investment firm, today announced the promotions of Christina Reszka and Philip Zaorski to Partner on the Growth Buyout team.

Frazier Healthcare Partners announced today the promotion of four Life Sciences team members: Jamie Brush, M.D., to General Partner and Portfolio Manager, David Topper to Partner, Capital Markets, Liz Park to Principal, Investor Relations, and Joe Cabral to Senior Associate.

Frazier Healthcare Partners announced today the closing of Frazier Life Sciences Public Fund, L.P., exceeding its target and closing on nearly $830 million in capital commitments in an oversubscribed fundraise.

Frazier Healthcare Partners, a leading private equity and venture capital firm focused exclusively on the healthcare industry, is pleased to announce that Amanda Bosse has joined the firm’s Growth Buyout team as an Executive in Residence. Ms. Bosse will work alongside the firm to develop and execute investment strategies focused on differentiated outsourced pharmaceutical contract manufacturing and scientific services enabling advanced therapies. In this role, Ms. Bosse will focus on the sourcing, diligence, and leadership of a new platform that enables the next generation of life sciences products and personalized medicine.

Frazier Healthcare Partners announced the addition of Maria Fardis, Ph.D. as a Venture Partner on the Life Sciences team. She has over 20 years of scientific and management experience in numerous public and private biopharmaceutical companies. She is also the Chief Executive Officer of 4PinesCo, Inc., a Frazier-founded search company focused on identifying, in-licensing, and developing high-quality therapeutic candidates.